Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

Shares of pharmaceutical companies fell across Europe and Asia after President Donald Trump said he planned to order a cut in ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda Pharmaceutical Co. Currently has a Zacks ... the components of the Momentum Style Score for TAK that show why this company shows promise as a solid momentum pick. Looking at a stock's ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

Takedas dengue vaccine Qdenga is set to launch in India by 2026 through a partnership with Biological E offering hope against rising dengue cases with local production and global backing ...